An interventional study of PET/MRI with 18F-FDG and [68Ga]Ga-CTR-FAPI in Rectal Cancer, Lymph Node Metastases and PET / MR, sponsored by Peking University Cancer Hospital & Institute. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Peking University Cancer Hospital & Institute · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute — 9 open to participants now, 10 under way, 2 of them phase 3. Rectal Neoplasms · Peking University Cancer Hospital & Institute.
Among the 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 with no phase, and was the 15th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →9 of the 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute are open now, in 1 country. Recruiting first, the newest first:
Peking University Cancer Hospital & Institute · Sites in China
Ages 18+
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–75
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–85
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–75
Peking University Cancer Hospital & Institute
Ages 18–75
By country, each count listing its studies:
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 2
First in 2016; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 81 across the 13 interventional studies, 68 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking University Cancer Hospital & Institute is the lead sponsor of 269 studies on the registry; 128 are open to participants now.
3 of the studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06229041Phase 3Peking University Cancer Hospital & InstituteTotal Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | 2027-10-01 |
| NCT07366047Peking University Cancer Hospital & InstituteAutologous Probiotics in Patients With Defunctioning Ileostomy Following LAR for Rectal Cancer | 2027-06-30 |
| NCT07833319Peking University Cancer Hospital & InstituteLocal Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Rectal Neoplasms by Peking University Cancer Hospital & Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, single-center, diagnostic study designed to compare the accuracy of [68Ga]Ga-CTR-FAPI PET/MRI and [18]F-FDG PET/MRI for the detection of lymph node metastasis in patients with initially untreated, resectable middle to high rectal cancer. The study aims to evaluate whether [68Ga]Ga-CTR-FAPI PET/MRI provides higher sensitivity and specificity than traditional 18F-FDG PET/MRI at both the patient level and the lymph node level.
Accurate preoperative staging of colorectal cancer is crucial for formulating treatment plans and improving patient prognosis. While conventional MRI and 18F-FDG PET/MRI are utilized, they face limitations such as false positives due to inflammatory lymph nodes or fibrotic scars. Fibroblast activating protein inhibitor (FAPI) specifically targets tumor-associated fibroblasts, potentially reducing false-positive rates by avoiding non-specific uptake in inflammatory areas.
This study aims to cross-validate the diagnostic efficacy of these two probes through a precise imaging-pathology matching technique. All enrolled patients will sequentially undergo both [68Ga]Ga-CTR-FAPI PET/MRI and 18F-FDG PET/MRI within 30 days prior to radical surgery. Following surgery, fresh mesorectal specimens will be precisely sectioned and matched to preoperative anatomical imaging maps. By leveraging a well-established node-by-node matching and identification methodology with high accuracy, this study ensures the execution of spatial correlation between preoperative radiologic imaging and postoperative microscopic pathology. Through mapping individual lymph nodes, the study will analyze the root causes of false positives and negatives, and extract radiomics features to evaluate their correlation with the tumor microenvironment (e.g., fibroblast density, Ki-67 index).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with confirmed middle to high rectal adenocarcinoma who are scheduled for radical surgery.
Diagnostic Test: PET/MRI with 18F-FDG and [68Ga]Ga-CTR-FAPI
Diagnostic Test: 18F-FDG PET/MRI Description: Patients receive an intravenous injection of 18F-FDG (3.7-5.5 MBq/kg). Diagnostic Test: \[68Ga\]Ga-CTR-FAPI PET/MRI Description: Patients receive an intravenous injection of \[68Ga\]Ga-CTR-FAPI (1.8-3.7 MBq/kg).
Sensitivity and Specificity of Lymph Node Metastasis Detection
Comparison of the sensitivity and specificity of \[68Ga\]Ga-CTR-FAPI and 18F-FDG PET/MRI in determining lymph node metastasis at both the individual lymph node level and the patient level. Sensitivity is defined as the proportion of imaging-positive and pathology-positive nodes out of all pathology-positive nodes. Specificity is defined as the proportion of imaging-negative and pathology-negative nodes out of all pathology-negative nodes.
Time frame: Up to 30 days post-surgery
False Positive and False Negative Rates
Analysis of the false positive and false negative rates of FAPI and FDG imaging, exploring underlying pathological bases such as inflammation or micrometastasis.
Time frame: Up to 30 days post-surgery
Correlation Between Radiomics Features and Tumor Microenvironment
Extraction of lymph node radiomics features to evaluate their association with tumor microenvironmental markers, determined via automatic immunohistochemistry scoring.
Time frame: Up to 30 days post-surgery
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 20 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Cancer Hospital & Institute →